Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Bristol-Myers Halts Hepatitis C Drug Study on "Serious" Safety Issue

August 2, 2012

Citing the "emergence of a serious safety issue," Bristol-Myers Squibb Co. said Wednesday it was voluntarily suspending the Phase II study of a hepatitis C drug candidate, BMS-986094. Earlier this year, BMS paid $2.5 billion to acquire Inhibitex Inc., the company that developed the nucleotide polymerase inhibitor formerly known as INX-189. "The cause of the safety issue and any potential relationship to the study drug are unknown at this time," BMS said in a statement. The company currently is assessing all the study patients and will decide on next steps following an evaluation of patient data.

Back to other news for August 2012

Adapted from:
Wall Street Journal
08.02.2012; Saabira Chaudhuri


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement